The efficiency of high dose botulinum toxin type-A in the treatment of cerebral palsy
Alper İbrahim Dai 1 *
More Detail
1 Gazianep Üniversitesi, Tıp Fakültesi Çocuk Nörolojisi Bilim Dalı Gaziantep, Turkey
* Corresponding Author

Abstract

Objective: Cerebral palsy is the most common cause of severe physical disability in childhood. Botulinum toxin type A (BTX-A), has rapidly gained acceptance as a different treatment for spasticity. However, no consensus exists among clinicians about optimal dose of BTX-A in pediatric patients. Doses of 2-6 U/ kg bodyweight with a maximum total dose of 29U/kg have been reported. This study was conducted due to uncertain dosage rage in pediatric use.
Method: In this study, 12 patients with cerebral palsy and spastic eqinus foot deformity who referred to our center, were treated with BTX-A in the dosage of 25 U/kg. After treatment of BTX-A, patients were followed up total of 6 months. Three months after treatment, Gross motor functional measurement (GMFM) and Modified Ashwort scale (MAS) were done. At the same time, questionnaires (PCQ) were filled for possible side effects.
Results: Average age of 6 girls and 6 boys were 4.5 ± 2.8 years. GMFM and MAS were done before and 3 months after treatment and were found statistically significant (p<0.05). Muscle soreness was the most common symptom at PCQ forms.
Conclusion: Using these two objective scales and PCQ form, high dose of BTX-A treatment was found statistically successful. Larger dose of BTX-A was used which was considered safe, effective and better tolerated by children. Titration of the dose of BTX-A, should be individualized for each patient due to different level of spasticity affecting patients in different ways.

License

This is an open access article distributed under the Creative Commons Attribution License (CC BY 4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Research Article

https://doi.org/10.5799/ahinjs.01.2014.01.0366

J Clin Exp Invest, 2014 - Volume 5 Issue 1, pp. 93-97

Publication date: 11 Mar 2014

Article Views: 1446

Article Downloads: 1326

Open Access References How to cite this article